A selective, non-peptide antagonist of corticotropin releasing factor receptors (CRF1). It blocks CRF-induced adenylate cyclase activation and attenuates activation of the HPA axis by CRF. It displayed anxiolytic-like activity in the rat elevated plus-maze test; brain penetrant.
Form:
Pale Yellow Solid
Melting Point:
167-169 degrees C
Solubility:
DMSO, Methanol
Pfizer Compound
Lundkist, J. et al.: Eur. J. Pharmacol., 309, 195 (1996); Arbolius, L. et al.: J. pharmacol. Exp. Therap., 294, 588 (2000); Kehne, J.H. et al.: Neuropharmacol., 39, 1357 (2000);
Quick Search
